Recombinant Anti-Tau (phospho S199) antibody [EPR2401Y] (ab81268)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2401Y] to Tau (phospho S199)
- Suitable for: WB, Dot blot
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Tau (phospho S199) antibody [EPR2401Y]
See all Tau primary antibodies -
Description
Rabbit monoclonal [EPR2401Y] to Tau (phospho S199) -
Host species
Rabbit -
Specificity
The specificity of this antibody refers to P10636-8.
-
Tested applications
Suitable for: WB, Dot blotmore details
Unsuitable for: IHC-P -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Mouse cerebral cortex and human hippocampus tissue lysates, SH SY5Y cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
Dissociation constant (KD)
KD = 2.95 x 10 -12 M Learn more about KD -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 0.05% BSA, 40% Glycerol (glycerin, glycerine), 59% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2401Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab81268 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/5000 - 1/20000. Detects a band of approximately 55 kDa (predicted molecular weight: 79 kDa).
|
Dot blot |
1/1000.
|
Notes |
---|
WB
1/5000 - 1/20000. Detects a band of approximately 55 kDa (predicted molecular weight: 79 kDa). |
Dot blot
1/1000. |
Target
-
Function
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. -
Tissue specificity
Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system. -
Involvement in disease
Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. -
Sequence similarities
Contains 4 Tau/MAP repeats. -
Developmental stage
Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain. -
Domain
The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats. -
Post-translational
modificationsPhosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD. -
Cellular localization
Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components. - Information by UniProt
-
Database links
- Entrez Gene: 4137 Human
- Entrez Gene: 17762 Mouse
- Entrez Gene: 29477 Rat
- Omim: 157140 Human
- SwissProt: P10636 Human
- SwissProt: P10637 Mouse
- SwissProt: P19332 Rat
- Unigene: 101174 Human
see all -
Form
There are 9 isoforms produced by alternative splicing. -
Alternative names
- AI413597 antibody
- AW045860 antibody
- DDPAC antibody
see all
Images
-
All lanes : Anti-Tau (phospho S199) antibody [EPR2401Y] (ab81268) at 1/1000 dilution
Lane 1 : 293T cells transfected with an empty vector containing a flag tag whole cell lysate
Lane 2 : 293T cells transfected with a human Tau expression vector containing a flag whole cell lysate
Lane 3 : 293T cells transfected with a human MAP2 expression vector containing a flag whole cell lysate
Lane 4 : 293T cells transfected with a human MAP4 expression vector containing a flag whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)
Predicted band size: 79 kDa
Observed band size: 55-100 kDa why is the actual band size different from the predicted?
Exposure time: 1 secondBlocking/dilution buffer: 5% NFDM/TBST
-
Dot blot analysis using 1/1000 dilution ab81268 and Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) secondary at 1/100000 dilution.
Blocking and diluting buffer: 5% NFDM/TBST
Lane 1: Tau non-phospho peptide
Lane 2: Tau S199 phospho peptide
Lane 3: Tau S202 phospho peptide
Lane 4: Tau S199+S202 phospho peptide
Exposure time: 3 minutes
-
All lanes : Anti-Tau (phospho S199) antibody [EPR2401Y] (ab81268) at 1/1000 dilution
Lane 1 : Mouse cerebral cortex tissue lysate
Lane 2 : Mouse cerebral cortex tissue lysate, The membrane was incubated with phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Predicted band size: 79 kDa
Observed band size: 55 kDa why is the actual band size different from the predicted?
Exposure time: 5 secondsBlocking and dilution buffer: 5% NFDM/TBST.
-
All lanes : Anti-Tau (phospho S199) antibody [EPR2401Y] (ab81268) at 1/1000 dilution
Lane 1 : Human hippocampus tissue lysate
Lane 2 : Human hippocampus tissue lysate. The membrane was incubated with phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/2000 dilution
Predicted band size: 79 kDa
Observed band size: 55 kDa why is the actual band size different from the predicted?
Exposure time: 1 minuteBlocking and dilution buffer: 5% NFDM/TBST.
-
Dot blot analysis of Tau (pS199) peptide (Lane 1) and Tau non-phospho peptide (Lane 2) labelling Tau (pS199) with ab81268 at a dilution of 1/1000. ab97051 (peroxidase-conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/100000.
Exposure time: 3 minutes.
Blocking and dilution buffer: 5% NFDM/TBST. -
All lanes : Anti-Tau (phospho S199) antibody [EPR2401Y] (ab81268) at 1/20000 dilution
Lane 1 : SH SY5Y cell lysate
Lane 2 : SH SY5Y cell lysate treated with alkaline phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 79 kDa
Observed band size: 55 kDa why is the actual band size different from the predicted?
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab81268 has been referenced in 12 publications.
- Weidling IW et al. Mitochondrial DNA Manipulations Affect Tau Oligomerization. J Alzheimers Dis 77:149-163 (2020). PubMed: 32804126
- Guo S et al. Classic Prescription, Kai-Xin-San, Ameliorates Alzheimer's Disease as an Effective Multitarget Treatment: From Neurotransmitter to Protein Signaling Pathway. Oxid Med Cell Longev 2019:9096409 (2019). PubMed: 31354916
- Tuerde D et al. Isoform-independent and -dependent phosphorylation of microtubule-associated protein tau in mouse brain during postnatal development. J Biol Chem 293:1781-1793 (2018). PubMed: 29196605
- Zhang W et al. Knockdown of BACE1-AS by siRNA improves memory and learning behaviors in Alzheimer's disease animal model. Exp Ther Med 16:2080-2086 (2018). PubMed: 30186443
- Zhong L et al. Ellagic acid ameliorates learning and memory impairment in APP/PS1 transgenic mice via inhibition of ß-amyloid production and tau hyperphosphorylation. Exp Ther Med 16:4951-4958 (2018). PubMed: 30542451